Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
Status:
Recruiting
Trial end date:
2023-11-15
Target enrollment:
Participant gender:
Summary
This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase
inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular
response in a real world population.